Vireo Growth Inc. Announces $75 Million Financing and Acquisitions of Four Single State Operators
– $75 million equity financing at $0.625 per Vireo share will result in combined new entity having an industry-leading balance...
Epidemics
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with...
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
EYLEA HD demonstrated non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed...
ICF Awarded Over $40 Million In Contracts to Drive Health Innovation with Advanced Technology
NIH Initiatives Will Enhance Generative AI Usage and Health Data Discoverability RESTON, Va., Dec. 11, 2024 /PRNewswire/ -- ICF (NASDAQ:ICFI),...
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant...
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed...
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease...
Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008) Lirafugratinib is a potential best-in-class FGFR2...
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)Lirafugratinib is a potential best-in-class FGFR2 inhibitor...
NHI Announces Appointment of Candice Todd to the Board of Directors
MURFREESBORO, TN / ACCESSWIRE / December 2, 2024 / National Health Investors, Inc. (NYSE:NHI) announced today that Candice Todd will...
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study...
NHI Announces Retirement of W. Andrew Adams from the Board of Directors
MURFREESBORO, TN / ACCESSWIRE / November 5, 2024 / National Health Investors, Inc. (NYSE:NHI) announced today that after more than...
NHI Announces Fourth Quarter 2024 Dividend
MURFREESBORO, TN / ACCESSWIRE / November 5, 2024 / National Health Investors, Inc. (NYSE:NHI) announced today that it will pay...
ICF Appoints New Head of Corporate Development
Eric Hakimov to Lead M&A Strategy and Integration Efforts RESTON, Va., Nov. 4, 2024 /PRNewswire/ -- ICF (NASDAQ:ICFI), a global consulting...
Vireo Growth Inc. Announces New $10 Million Convertible Debt Facility
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), a cannabis...
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
Nearly 60% of patients with IgAN in the SPARTAN Study achieved complete remission when using FILSPARI as first-line treatment SPARTACUS...
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline...
Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema
88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual...
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT TrialSAN DIEGO, Oct....
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of...